1st Optimal Pricing Analysis and Total Cost

What 1st Optimal Charges and How Their Fee Structure Works

1st Optimal uses a cash-pay concierge model where patients pay out of pocket for consultations, lab work, medications, and ongoing management. No insurance is billed. This is common among performance and longevity clinics, where the business model relies on direct patient revenue rather than third-party reimbursement.

The base cost typically includes an initial consultation fee, a monthly or quarterly membership for physician access, and separate charges for laboratory panels and prescribed medications. Peptide therapies, testosterone replacement, thyroid protocols, and GLP-1 agonists each carry their own medication costs on top of the management fee. A patient on testosterone cypionate plus a peptide stack plus quarterly labs can expect to spend $800 to $1,500 per month all-in during the first year. That number drops somewhat in year two as initial diagnostic workups are complete.

For context, the Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends monitoring with serum testosterone, hematocrit, and PSA at 3, 6, and 12 months after initiation, then annually 1. The guideline-recommended monitoring schedule requires fewer lab draws than many concierge clinics order, which raises the question of whether additional panels deliver clinical value or simply inflate cost.

Breaking Down the Real Costs: Labs, Medications, and Add-Ons

Lab work is where concierge longevity clinics generate significant revenue. A comprehensive male or female hormone panel through a direct-pay lab like Quest or Labcorp costs $200 to $500 retail. Clinics that mark up panels or bundle proprietary "optimization panels" with 40 to 80 biomarkers can charge $600 to $1,200 per draw.

Medication costs vary widely. Generic testosterone cypionate 200 mg/mL (10 mL vial) costs $30 to $80 at a retail pharmacy with a GoodRx coupon. Through a compounding pharmacy affiliated with a concierge clinic, the same concentration may cost $120 to $250 per vial. The FDA has noted that compounded drugs "are not FDA-approved" and that patients should understand the difference in regulatory oversight 2.

Peptide therapies represent a growing cost center. BPC-157, CJC-1295/ipamorelin combinations, and other peptides are not FDA-approved for any indication. A typical peptide protocol runs $150 to $400 per month through compounding pharmacies. The FDA issued warning letters to multiple compounding pharmacies in 2023 and 2024 regarding peptide products, citing concerns about safety and efficacy 3.

GLP-1 agonists like semaglutide add another layer. Brand-name Wegovy carries a list price of approximately $1,349 per month 4. Compounded semaglutide, when available, may cost $300 to $600 per month through concierge clinics. The total medication bill for a patient on TRT plus peptides plus a GLP-1 can exceed $1,000 monthly before lab and consult fees.

Is 1st Optimal Legit? Evaluating the Clinical Model

The question of legitimacy has two parts: is the business operating within legal bounds, and are the prescribed interventions supported by evidence?

On the business side, cash-pay concierge medicine is a legal and increasingly common model. The American Academy of Family Physicians recognizes direct primary care as a valid practice structure, though it notes that "patients should understand what services are and are not included in the periodic fee" 5. Operating without insurance billing is not inherently problematic.

The clinical question is more nuanced. Testosterone replacement for men with confirmed hypogonadism (total testosterone consistently below 300 ng/dL with symptoms) has strong evidence. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine, found that testosterone replacement in hypogonadal men aged 45 to 80 with cardiovascular risk did not increase the incidence of major adverse cardiac events compared to placebo 6. That trial settled a long-standing safety concern.

The evidence is weaker for "optimization" in men with testosterone levels in the 400 to 600 ng/dL range who are asymptomatic. The Endocrine Society guideline explicitly recommends against testosterone therapy in men without clinical hypogonadism 1. Dr. Shalender Bhasin, the lead author of the Testosterone Trials (TTrials), stated that "testosterone treatment should be considered only in men with unequivocally low testosterone levels and symptoms consistent with androgen deficiency" 7.

For peptide therapies prescribed by clinics like 1st Optimal, the evidence base is thin. BPC-157 has shown promise in rodent models for tissue repair, but no randomized controlled trials in humans have been published as of 2026. The gap between animal data and clinical prescribing is significant, and patients should weigh this when evaluating cost.

1st Optimal vs. Alternatives: Price and Value Comparison

Several competitors operate in the same space with varying price points. Telehealth TRT clinics like Hone Health, Peter MD, and Marek Health charge $129 to $299 per month for testosterone management including labs. Concierge longevity practices like Fountain Life charge $7,500 to $19,500 annually for comprehensive diagnostics including whole-body MRI and coronary calcium scoring.

The value calculation depends on what you are paying for. A straightforward TRT protocol (diagnosis, testosterone cypionate, standard monitoring) can be managed for $150 to $250 per month through a telehealth platform or a local endocrinologist who accepts insurance. If your insurance covers the visits and labs, out-of-pocket costs for TRT may be as low as $50 to $100 per month.

Where concierge clinics differentiate is in the breadth of interventions and the time spent per visit. A 60-minute initial consult reviewing comprehensive labs, lifestyle factors, sleep architecture, and body composition is rarely available in a 15-minute insurance-based visit. The question is whether that extra time translates to better outcomes.

A 2020 systematic review in the Annals of Internal Medicine examined health outcomes in concierge and direct primary care models and found "limited evidence" that these models improve clinical outcomes compared to traditional primary care, though patient satisfaction was consistently higher 8. Satisfaction is not a trivial outcome, but it should be distinguished from clinical efficacy when spending $10,000+ annually.

Which Interventions Have the Strongest Evidence?

Not all services offered by performance and longevity clinics carry equal evidence. Patients evaluating 1st Optimal or similar practices benefit from understanding which interventions are well-supported and which are speculative.

Testosterone replacement in confirmed hypogonadism is strongly supported. The TTrials demonstrated improvements in sexual function, walking distance, and bone mineral density in hypogonadal men over 65 7. TRAVERSE confirmed cardiovascular safety 6. This is a legitimate medical therapy with a defined patient population.

GLP-1 agonists for obesity have strong data. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo 9. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks 10. These are among the most effective pharmacological weight-loss interventions ever studied.

Thyroid optimization in subclinical hypothyroidism is more debatable. The TRUST trial (N=737), published in the New England Journal of Medicine, found that levothyroxine did not improve symptoms or quality of life in adults aged 65 and older with subclinical hypothyroidism (TSH 4.6 to 19.9 mIU/L) 11. The American Thyroid Association recommends against routine treatment when TSH is below 10 mIU/L in most patients 12. Clinics that "optimize" thyroid levels in asymptomatic patients with mildly elevated TSH are prescribing outside guideline recommendations.

Peptide stacks (BPC-157, CJC-1295/ipamorelin, PT-141) lack Phase III clinical trial data. Growth hormone secretagogue peptides have shown modest GH elevation in small studies, but long-term safety and efficacy data in healthy adults pursuing "optimization" do not exist. The Endocrine Society's 2011 guideline on GH use in adults states that "GH therapy is not recommended for anti-aging purposes" 13.

The Hidden Costs Patients Miss

Beyond the sticker price, several costs are easy to overlook. Compounding pharmacy markups, shipping fees for temperature-sensitive peptides, and ancillary medications (anastrozole for estrogen management, HCG for fertility preservation) each add $50 to $200 per month.

Lab panel frequency matters. A clinic ordering labs every 6 weeks during the "optimization phase" will bill 8 to 9 panels in the first year versus the 3 to 4 that clinical guidelines recommend for standard TRT monitoring. At $400 to $800 per panel, the difference is $2,000 to $4,000.

Supplement recommendations are another revenue stream. Many concierge clinics sell or recommend branded supplements with significant markups. A 2015 analysis published in JAMA Internal Medicine found that the supplement industry's marketing claims frequently lack adequate supporting evidence 14. Patients should evaluate whether recommended supplements have clinical trial support before adding $100 to $300 per month in nutraceutical costs.

There is also the opportunity cost. The $6,000 to $15,000 spent in year one at a concierge longevity clinic could fund 2 to 3 years of standard endocrinology care with insurance, including all labs, medications, and office visits. For a patient with straightforward hypogonadism, the math may favor the conventional route.

When Concierge Longevity Medicine Makes Financial Sense

Concierge models deliver the most value for patients with complex, multi-system concerns that benefit from extended consultations and coordinated protocols. A 55-year-old man with hypogonadism, metabolic syndrome, sleep apnea, and early cognitive complaints may benefit from a clinician who can spend 90 minutes integrating those problems into a single plan. The fragmented specialist model (endocrinologist, cardiologist, sleep medicine, neuropsychologist) can be more expensive in total and slower to coordinate.

Patients who have failed to get answers through traditional channels also represent a reasonable use case. The average primary care visit lasts 18 minutes, according to a 2019 analysis in the Journal of General Internal Medicine 15. Complex optimization discussions rarely fit that window.

The worst value proposition is for healthy adults in their 20s and 30s with normal biomarkers who are seeking pharmacological enhancement beyond their physiological baseline. The evidence supporting hormone "optimization" above mid-range normal in asymptomatic individuals is sparse. As the Endocrine Society has stated, supraphysiological dosing of testosterone is associated with erythrocytosis, acne, and potential cardiovascular risks without established benefit in eugonadal men 1.

How to Evaluate Whether 1st Optimal Is Right for You

Before committing to any cash-pay concierge clinic, request a complete fee schedule in writing. Ask specifically about consultation fees, lab costs (and whether you can use your own insurance for labs), medication costs through their affiliated pharmacy versus retail alternatives, and whether there are cancellation or minimum-commitment clauses.

Get baseline labs independently first. A complete male or female hormone panel through a direct-pay lab service costs $150 to $300 and gives you data to compare against what the clinic recommends. If your testosterone, thyroid, metabolic panel, and CBC are all within normal ranges and you are asymptomatic, the clinical justification for aggressive intervention is weak regardless of what a sales consultation suggests.

Dr. Bradley Anawalt, chief of medicine at the University of Washington Medical Center and an Endocrine Society guideline committee member, has noted that "the commercialization of testosterone therapy has led to prescribing in populations where benefit has not been demonstrated" 1. That observation applies equally to the broader longevity medicine market.

The annual cost of a concierge longevity membership should be measured against the specific, evidence-based interventions you receive, not against the promise of optimization. A $500/month membership that results in guideline-concordant TRT management with appropriate monitoring is defensible. The same membership funding off-label peptide stacks without human trial data is a different risk-benefit calculation entirely. Track every dollar, verify every claim against published data, and get a second opinion from a board-certified endocrinologist before committing to a protocol that costs more than $5,000 per year.